Company Filing History:
1 out of 1 
1 out of 1,290 
Years Active: 2025
Title: Jeonghyun Ryou: Innovator in Cancer Immunotherapy
Introduction
Jeonghyun Ryou, an esteemed inventor based in Gyeonggi-do, South Korea, has made significant strides in the field of cancer treatment. With a focus on the tumor immune microenvironment, Ryou's innovative approach combines immunotherapy with a novel substance to combat cancer effectively.
Latest Patents
Ryou holds one patent that pioneers a new method for cancer treatment. His patent, titled "Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer," details a unique combination of a substance designed to inhibit the function of extracellular TCTP (translationally controlled tumor protein) released from tumor cells and a cancer immunotherapeutic agent, ideally an immune checkpoint inhibitor. This combination aims to act as an enhancer of anti-tumor immune cells, such as T cells and natural killer (NK) cells, while combating immunosuppressive cells within the tumor immune microenvironment.
Career Highlights
Throughout his career, Jeonghyun Ryou has worked with prominent organizations such as Boostimmune, Inc. and the University of Tokyo. His role in these institutions has contributed to the advancement of research and development in cancer immunotherapy, showcasing his dedication to creating innovative solutions to complex health challenges.
Collaborations
Ryou’s collaborative spirit is evident in his work alongside notable colleagues, including Gwanghee Lee and Jiwon Huh. Together, they share a commitment to innovation and excellence in cancer research, further enriching the field with diverse perspectives and expertise.
Conclusion
Jeonghyun Ryou’s contributions to cancer treatment through his patent represent a significant advancement in the medical field. By focusing on the tumor immune microenvironment and combining innovative therapeutic agents, Ryou’s work holds promise for improving cancer treatment outcomes and enhancing the understanding of immune responses in cancer therapy.